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Parkinson’s disease (PD), the most common neurodegenerative disorder, is
characterized by abnormal accumulation of α-synuclein aggregates known as Lewy
bodies (LB) and loss of nigrostriatal dopaminergic neurons. Recent neuroimaging studies
suggest that in the early phases of PD, synaptic and axonal damage anticipate the onset
of a frank neuronal death. Paralleling, even post mortem studies on the brain of affected
patients and on animal models support that synapses might represent the primary
sites of functional and pathological changes. Indeed, α-synuclein microaggregation
and spreading at terminals, by dysregulating the synaptic junction, would block
neurotransmitter release, thus triggering a retrograde neurodegenerative process ending
with neuronal cell loss by proceeding through the axons. Rather than neurodegeneration,
loss of dopaminergic neuronal endings and axons could thus underlie the onset
of connectome dysfunction and symptoms in PD and parkinsonisms. However, the
manifold biases deriving from the interpretation of human brain imaging data hinder
the validation of this hypothesis. Here, we present pivotal evidence supporting that
novel comparative brain imaging studies, in patients and experimental models of PD
in preliminary stages of disease, could be instrumental for proving whether synaptic
endings are the sites where degeneration begins and initiating the factual achievement
of disease modifying approaches. The need for such investigations is timely to define an
early therapeutic window of intervention to attempt disease halting by terminal and/or
axonal healing.
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PERSPECTIVE
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder. The brain
of affected patients is characterized by accumulation of insoluble α-synuclein aggregates in Lewy
bodies (LB) and Lewy neurites (LN; Spillantini et al., 1997) and degeneration of the nigrostriatal
dopamine system (Surmeier et al., 2017). It has become increasingly evident that in addition to
motor, also non-motor symptoms like depression, olfactory dysfunction, constipation and idiopatic
REM sleep behavior disorder (IRBD), could precede the onset of movement disturbances in PD by
many years (Chaudhuri et al., 2011; Iranzo et al., 2011; Fereshtehnejad et al., 2017).
On this line, evidence supports that PD patients exhibit dysfunctions of multi-neurotransmitter
pathways as well as central and peripheral α-synuclein accumulation (Titova et al., 2017). The
different functional reserve of affected neuronal networks originating in the central and peripheral
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nervous system may steer the resilience to symptom onset
(Engelender and Isacson, 2017). Prodromal signs would manifest
because distinct populations of central and peripheral neurons
hold increased predisposition toward α-synuclein accumulation
and low functional reserve. Conversely, the onset of motor
symptoms originating from nigrostriatal pathology, would be
delayed by the larger functional reserve of midbrain dopamine
neurons and basal ganglia circuits (Engelender and Isacson,
2017). Therefore, prodromal markers may be identified, opening
new hopes for the detection of early pre-degenerative changes
that could be instrumental to understand when and where this
disorder originates.
It has been described that a series of specific cell-autonomous
pathways may significantly contribute to the selective
vulnerability of nigrostriatal dopaminergic neurons to
α-synuclein accumulation (Surmeier et al., 2017). These
include their intrinsic pacemaking activity, Ca2+ loading due
to sustained voltage-gated Ca2+ channel opening, their long
and widely diffused axonal arborization and the selective
dependency on α-synuclein for synaptic activity. However,
the slow progression of disease and the decreasing effect of
dopamine substitution therapy over time supports a gradually
increasing presynaptic failure that precedes neuronal cell death
(Schulz-Schaeffer, 2015). Consistently, recent neuroimaging
studies show terminal damage anticipating axonal degeneration,
which in turn culminates in dopamine cell loss. Measures
of dopamine transporter (DAT) activity in the nigrostriatal
and mesolimbic systems in patients in the early phases of PD
has unraveled initially more prominent neurodegeneration in
dopamine nerve terminals and axons and less severe in the
substantia nigra (Caminiti et al., 2017). Magnetic resonance
imaging (MRI) studies with diffusion tensor imaging (DTI), a
technique allowing detection of microstructural white matter
pathology (Tir et al., 2009; Olde Dubbelink et al., 2013; Wang
et al., 2017) have led to similar results. In addition, asymmetric
nigrostriatal neurodegeneration in early PD mirrors the initial
asymmetry in clinical manifestations (Wang et al., 2015). Most
strikingly, in IRBD subjects the decrease of striatal DAT binding
reflects the rate of progressive dopaminergic dysfunction (Iranzo
et al., 2011). The significant reduction in striatal DAT binding,
with preserved nigral signal measured with 7T MRI, that we
observed in a still asymptomatic family member carrying the
Leucine-rich repeat kinase 2 (LRRK2) G2019S mutation, further
supports the concept of synaptic dysfunction anticipating
Nigrosome-1 degeneration even in familial PD (Ceravolo et al.,
2015). Moreover, a study on PD patients with abnormal bilateral
DAT binding analyzed by 3 Tesla (3T) MRI revealed that
14 among the 126 PD patients had bilaterally intact Nigrosome-1
and that this parameter was unilaterally unaffected in 7 among
the 126 PD patients (Bae et al., 2016).
In line with the idea that early terminal damage mirrors the
progression of dopamine denervation rather than cell loss, Saari
et al. (2017) have provided evidence suggesting lack of correlation
between number of substantia nigra neurons and striatal DAT
loss in PD. This further reinforces the concept of reduced
DAT binding reflecting axonal dysfunction, abatement of DAT
expression or a decrease of its membrane expression rather than
the number of viable neurons. Consistently, PD patients in the
early phases have been found to display a temporal longitudinal
evolution of compensatory changes in the striatum. Indeed,
striatal DAT decrease was found to anticipate the loss of vesicular
monoamine transporter 2 (VMAT-2) that rapidly disappears
and is considered an optimal biomarker to detect nigrostriatal
damage in the presymptomatic phases of the disorder (Chen
et al., 2008; Nandhagopal et al., 2011).When taken together, these
evidences seem particularly consistent with the possibility that in
PD degeneration begins at synaptic terminals.
Studies support that α-synuclein microaggregation at the
synapse may be the causative factor initiating dopamine
neuron degeneration in PD by impinging on synaptic activity
(Schulz-Schaeffer, 2015; Calo et al., 2016). Synaptic α-synuclein
microaggregation occurs in the early stages of the degenerative
process and in the post-mortem brain of PD patients the load
of α-synuclein at terminals is several orders of magnitude
higher than its content within LB (Schulz-Schaeffer, 2010).
Alpha-synuclein is physiologically enriched at synaptic terminals
where it controls neurotransmitter reuptake and homeostasis
by regulating transporters as well as synaptic vesicle fusion,
clustering, and trafficking between the reserve and ready-
releasable pools (Burré, 2015). Alpha-synuclein multimers
and aggregates can cluster synaptic vesicles, attenuate their
recycling and impair the distribution of associated proteins
that are modulated by α-synuclein in physiological conditions
(Garcia-Reitböck et al., 2010; Bellucci et al., 2011; Lundblad
et al., 2012; Wang et al., 2014; Zaltieri et al., 2015). Among
them, Soluble NSF Attachment Protein Receptor (SNARE)
proteins, synapsin III, VMAT-2 and the DAT are altered
in the nigrostriatal system of experimental models of PD
(Garcia-Reitböck et al., 2010; Bellucci et al., 2011; Lundblad
et al., 2012; Zaltieri et al., 2015). Notably, mice transgenic
for wild type α-synuclein display augmented striatal tonic
dopamine release and increased locomotor activity before
the onset of striatal denervation and L-DOPA-responsive
motor phenotype (Lam et al., 2011), thus supporting that
early striatal synaptic dysfunctions precede neurodegeneration.
In addition, the early paradoxical increase of dopamine
in the olfactory bulb in the absence of motor impairment
that has been recently found to occur in 1-Methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated monkeys
(Pifl et al., 2017) hints that synaptic changes precede the
onset of PD symptoms. Since cell-to-cell transmission of
α-synuclein proceeds via trans-synaptic spreading through
intact neuronal connections (Ulusoy et al., 2015), it is likely
that in the initial phases of PD its deposition at terminals
might be the predominant factor prompting even diffusion
of pathology (Longhena et al., 2017). Loss of neuronal
connections deriving from α-synuclein deposition at terminals
could trigger axonal damage, which by proceeding in a
retrograde modality, would end with neuronal cell body
degeneration (Figure 1). This could occur through the collapse
of intracellular trafficking, with the massive axonal harbor
of midbrain dopaminergic neurons constituting a pivotal
vulnerability factor to intracellular trafficking defects (Hunn
et al., 2015).
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FIGURE 1 | The putative organization of the dopaminergic synapse in healthy condition and in Parkinson’s disease (PD) is presented in relation with nigrostriatal
neuron degeneration, connectome function and the disease staging. (A) Correct organization of synaptic vesicle pools in a dopaminergic striatal terminal in the
healthy brain. (B) Retrograde synapse-to-cell-body degeneration initiating and perpetrating nigrostriatal connectome dysfunction in PD. In the prodromal phases of
PD, microaggregation of α-synuclein at synaptic terminals progressively changes the organization of synaptic vesicle pools, reduces dopamine release, alters
dopamine turnover and decreases dopamine transporter (DAT) membrane content but nigral neuron loss is negligible. Alpha-synuclein can also spread from
terminals. DAT binding is reduced with mild to absent alterations of diffusion tensor imaging (DTI) and lack of Nigrosome-1 decrease. This synaptic impairment may
initiate connectome dysfunctions in the absence of marked synapse loss or axonal and cell body degeneration. In the early stages of PD, the onset of symptoms is
related to the beginning of connectome deficits that mainly arise from synaptic and axonal loss and only to a lesser extent to nigral cell loss. DAT binding and DTI
abnormalities are accompanied by a partial or unilateral decrease of Nigrosome-1. Finally, in the advanced phases of the disease, broad synaptic, axonal and cell
body degeneration that can be detected by integrating multiple imaging techniques, concomitantly participate to disease progression. PP, Proximal pool; RRP, ready
releasable pool, RP, reserve pool.
Therefore, deficits of functional connectivity in the
early phases of PD, may underlie the onset of motor
and non-motor symptoms and reflect the occurrence
of synaptic and axonal degeneration rather than
neuronal death. Nonetheless, this still needs to be
validated.
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The demand of imaging studies aimed at confirming whether
neuronal endings are the sites where neurodegeneration begins
in PD is thus urgent. In addition, it is timely to define an
earlier imaging window. The establishment of novel criteria
for the identification of patients in the prodromal phases
of disease can offer new opportunities for the establishment
of novel comparative brain imaging studies on such subjects
and experimental models. These are warranted to provide
new insights on when and how nerve terminal degeneration
originates and for revising the staging of these disorders. Indeed,
when taking into consideration the centrality of nigrostriatal
degeneration in the onset of motor symptoms, we could envisage
that in the prodromal/early stages of PD there is a phase when
striatal synaptic impairment occurs in the absence of axonal
degeneration and only subsequently progresses toward nigral cell
loss. However, the molecular events involved in this process can
only partially be pictured through the integration of data deriving
from human brain imaging and studies in experimental models
of PD, but we still miss comparative analysis demonstrating
how connectome dysfunction originates and progresses. Indeed,
pioneering studies have demonstrated a high correlation between
positron emission tomography based striatal DAT imaging or
DTI and immunostaining values in experimental models of
PD such as 6-hydroxydopamine-injected rats and MPTP-treated
monkeys (Blesa et al., 2012; Hikishima et al., 2015; Molinet-
Dronda et al., 2015), suggesting that comparative analysis is
instrumental to decipher live imaging results. This could allow
to shed light on the precise molecular alterations underlying
single photon emission computed tomography (SPECT), MRI
and DTI abnormalities in the early phases of PD. What is more,
studies on experimental models of PD should finally benefit
from the application of intact brain analysis, which allows to
visualize whole nigrostriatal neurons and to discriminate their
different conformations (Lerner et al., 2015). This technique
could be helpful for evaluating the effective relevance of
brain imaging biases deriving from the fact that an enormous
amount of synapses derive from a single dopaminergic neuron
(Matsuda et al., 2009), as this implies that while the loss of
few nigral neurons might be below of the imaging threshold,
the loss of the corresponding terminal fields might be easily
detectable with imaging. Furthermore, fluorescence lifetime
imaging (FLIM), that can detect of α-synuclein conformational
changes and oligomers (Outeiro et al., 2009), when coupled
with two-photon imaging, could represent an invaluable tool
to connect terminal loss with α-synuclein aggregation or
to define the pathological ‘‘interactome’’ of the protein that
drives neuronal degeneration. Comparative MRI-based studies
in animal models undergoing ex vivo or intravital microscopy
analysis should thus be undertaken to enable a more precise
interpretation of data deriving from human brain imaging.
These investigations, allowing the correlation between results
from human brain imaging and the underlying microscopic
neuropathological alterations, could definitely give us novel
decoding keys to understand timing and features of connectome
dysfunction in the prodromal phases of PD. Hopefully, if brain
imaging could allow to determine whether synaptic endings are
the sites where PD begins, we may expect to identify a novel
therapeutic window of intervention to halt or delay disease
progression.
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